|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DNAJC1 |
Gene summary for DNAJC1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DNAJC1 | Gene ID | 64215 |
| Gene name | DnaJ heat shock protein family (Hsp40) member C1 | |
| Gene Alias | DNAJL1 | |
| Cytomap | 10p12.31 | |
| Gene Type | protein-coding | GO ID | GO:0006412 | UniProtAcc | Q96KC8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 64215 | DNAJC1 | GSM4909282 | Human | Breast | IDC | 3.58e-02 | 9.73e-02 | -0.0288 |
| 64215 | DNAJC1 | GSM4909285 | Human | Breast | IDC | 5.36e-06 | 2.19e-01 | 0.21 |
| 64215 | DNAJC1 | GSM4909291 | Human | Breast | IDC | 1.13e-04 | 3.32e-01 | 0.1753 |
| 64215 | DNAJC1 | GSM4909296 | Human | Breast | IDC | 3.92e-08 | -1.83e-02 | 0.1524 |
| 64215 | DNAJC1 | GSM4909297 | Human | Breast | IDC | 2.97e-07 | -8.78e-02 | 0.1517 |
| 64215 | DNAJC1 | GSM4909301 | Human | Breast | IDC | 4.99e-02 | 1.62e-01 | 0.1577 |
| 64215 | DNAJC1 | GSM4909302 | Human | Breast | IDC | 6.38e-14 | 4.52e-01 | 0.1545 |
| 64215 | DNAJC1 | GSM4909307 | Human | Breast | IDC | 7.94e-24 | 5.90e-01 | 0.1569 |
| 64215 | DNAJC1 | GSM4909308 | Human | Breast | IDC | 2.31e-26 | 5.96e-01 | 0.158 |
| 64215 | DNAJC1 | GSM4909311 | Human | Breast | IDC | 2.28e-17 | -1.26e-01 | 0.1534 |
| 64215 | DNAJC1 | GSM4909312 | Human | Breast | IDC | 1.55e-14 | 2.77e-01 | 0.1552 |
| 64215 | DNAJC1 | GSM4909319 | Human | Breast | IDC | 3.31e-35 | 1.05e-01 | 0.1563 |
| 64215 | DNAJC1 | GSM4909321 | Human | Breast | IDC | 4.99e-12 | 1.03e-01 | 0.1559 |
| 64215 | DNAJC1 | M5 | Human | Breast | IDC | 1.67e-07 | 6.64e-01 | 0.1598 |
| 64215 | DNAJC1 | NCCBC14 | Human | Breast | DCIS | 3.62e-03 | -2.37e-01 | 0.2021 |
| 64215 | DNAJC1 | NCCBC5 | Human | Breast | DCIS | 7.62e-05 | -8.00e-02 | 0.2046 |
| 64215 | DNAJC1 | P1 | Human | Breast | IDC | 1.45e-10 | -2.15e-01 | 0.1527 |
| 64215 | DNAJC1 | P2 | Human | Breast | IDC | 8.37e-03 | -1.20e-01 | 0.21 |
| 64215 | DNAJC1 | DCIS2 | Human | Breast | DCIS | 5.71e-47 | 1.51e-01 | 0.0085 |
| 64215 | DNAJC1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.85e-10 | -3.62e-01 | 0.0155 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004586114 | Breast | IDC | negative regulation of proteolysis | 70/1434 | 351/18723 | 8.21e-14 | 2.22e-11 | 70 |
| GO:000645713 | Breast | IDC | protein folding | 47/1434 | 212/18723 | 2.31e-11 | 3.86e-09 | 47 |
| GO:000641714 | Breast | IDC | regulation of translation | 74/1434 | 468/18723 | 1.67e-09 | 1.53e-07 | 74 |
| GO:005070812 | Breast | IDC | regulation of protein secretion | 36/1434 | 268/18723 | 6.93e-04 | 8.50e-03 | 36 |
| GO:007169212 | Breast | IDC | protein localization to extracellular region | 42/1434 | 368/18723 | 6.13e-03 | 4.38e-02 | 42 |
| GO:000930613 | Breast | IDC | protein secretion | 41/1434 | 359/18723 | 6.64e-03 | 4.63e-02 | 41 |
| GO:003559213 | Breast | IDC | establishment of protein localization to extracellular region | 41/1434 | 360/18723 | 6.96e-03 | 4.81e-02 | 41 |
| GO:000645723 | Breast | DCIS | protein folding | 47/1390 | 212/18723 | 7.84e-12 | 1.53e-09 | 47 |
| GO:004586123 | Breast | DCIS | negative regulation of proteolysis | 63/1390 | 351/18723 | 4.39e-11 | 6.06e-09 | 63 |
| GO:000641724 | Breast | DCIS | regulation of translation | 72/1390 | 468/18723 | 2.46e-09 | 2.17e-07 | 72 |
| GO:005070822 | Breast | DCIS | regulation of protein secretion | 35/1390 | 268/18723 | 7.83e-04 | 9.11e-03 | 35 |
| GO:007169222 | Breast | DCIS | protein localization to extracellular region | 41/1390 | 368/18723 | 6.01e-03 | 4.29e-02 | 41 |
| GO:000930622 | Breast | DCIS | protein secretion | 40/1390 | 359/18723 | 6.59e-03 | 4.61e-02 | 40 |
| GO:003559222 | Breast | DCIS | establishment of protein localization to extracellular region | 40/1390 | 360/18723 | 6.90e-03 | 4.77e-02 | 40 |
| GO:004603410 | Cervix | CC | ATP metabolic process | 90/2311 | 277/18723 | 7.90e-19 | 2.36e-15 | 90 |
| GO:000611910 | Cervix | CC | oxidative phosphorylation | 55/2311 | 141/18723 | 7.12e-16 | 1.42e-12 | 55 |
| GO:00090609 | Cervix | CC | aerobic respiration | 60/2311 | 189/18723 | 1.59e-12 | 6.36e-10 | 60 |
| GO:00427739 | Cervix | CC | ATP synthesis coupled electron transport | 38/2311 | 95/18723 | 8.45e-12 | 2.66e-09 | 38 |
| GO:00427759 | Cervix | CC | mitochondrial ATP synthesis coupled electron transport | 38/2311 | 95/18723 | 8.45e-12 | 2.66e-09 | 38 |
| GO:00196469 | Cervix | CC | aerobic electron transport chain | 36/2311 | 87/18723 | 9.15e-12 | 2.74e-09 | 36 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0414124 | Breast | IDC | Protein processing in endoplasmic reticulum | 36/867 | 174/8465 | 2.73e-05 | 2.86e-04 | 2.14e-04 | 36 |
| hsa0414134 | Breast | IDC | Protein processing in endoplasmic reticulum | 36/867 | 174/8465 | 2.73e-05 | 2.86e-04 | 2.14e-04 | 36 |
| hsa0414143 | Breast | DCIS | Protein processing in endoplasmic reticulum | 36/846 | 174/8465 | 1.60e-05 | 1.91e-04 | 1.41e-04 | 36 |
| hsa0414153 | Breast | DCIS | Protein processing in endoplasmic reticulum | 36/846 | 174/8465 | 1.60e-05 | 1.91e-04 | 1.41e-04 | 36 |
| hsa04141 | Colorectum | AD | Protein processing in endoplasmic reticulum | 80/2092 | 174/8465 | 5.96e-10 | 1.25e-08 | 7.96e-09 | 80 |
| hsa041411 | Colorectum | AD | Protein processing in endoplasmic reticulum | 80/2092 | 174/8465 | 5.96e-10 | 1.25e-08 | 7.96e-09 | 80 |
| hsa041414 | Colorectum | MSS | Protein processing in endoplasmic reticulum | 75/1875 | 174/8465 | 3.78e-10 | 8.44e-09 | 5.17e-09 | 75 |
| hsa041415 | Colorectum | MSS | Protein processing in endoplasmic reticulum | 75/1875 | 174/8465 | 3.78e-10 | 8.44e-09 | 5.17e-09 | 75 |
| hsa041418 | Colorectum | FAP | Protein processing in endoplasmic reticulum | 50/1404 | 174/8465 | 3.64e-05 | 3.68e-04 | 2.24e-04 | 50 |
| hsa041419 | Colorectum | FAP | Protein processing in endoplasmic reticulum | 50/1404 | 174/8465 | 3.64e-05 | 3.68e-04 | 2.24e-04 | 50 |
| hsa0414139 | Esophagus | HGIN | Protein processing in endoplasmic reticulum | 67/1383 | 174/8465 | 1.06e-12 | 2.16e-11 | 1.72e-11 | 67 |
| hsa04141114 | Esophagus | HGIN | Protein processing in endoplasmic reticulum | 67/1383 | 174/8465 | 1.06e-12 | 2.16e-11 | 1.72e-11 | 67 |
| hsa04141211 | Esophagus | ESCC | Protein processing in endoplasmic reticulum | 147/4205 | 174/8465 | 3.29e-22 | 1.10e-19 | 5.64e-20 | 147 |
| hsa04141310 | Esophagus | ESCC | Protein processing in endoplasmic reticulum | 147/4205 | 174/8465 | 3.29e-22 | 1.10e-19 | 5.64e-20 | 147 |
| hsa0414114 | Liver | Cirrhotic | Protein processing in endoplasmic reticulum | 114/2530 | 174/8465 | 1.16e-22 | 9.67e-21 | 5.96e-21 | 114 |
| hsa0414115 | Liver | Cirrhotic | Protein processing in endoplasmic reticulum | 114/2530 | 174/8465 | 1.16e-22 | 9.67e-21 | 5.96e-21 | 114 |
| hsa0414122 | Liver | HCC | Protein processing in endoplasmic reticulum | 146/4020 | 174/8465 | 7.34e-24 | 2.46e-21 | 1.37e-21 | 146 |
| hsa0414132 | Liver | HCC | Protein processing in endoplasmic reticulum | 146/4020 | 174/8465 | 7.34e-24 | 2.46e-21 | 1.37e-21 | 146 |
| hsa0414116 | Lung | IAC | Protein processing in endoplasmic reticulum | 37/1053 | 174/8465 | 6.53e-04 | 5.73e-03 | 3.81e-03 | 37 |
| hsa0414117 | Lung | IAC | Protein processing in endoplasmic reticulum | 37/1053 | 174/8465 | 6.53e-04 | 5.73e-03 | 3.81e-03 | 37 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DNAJC1 | SNV | Missense_Mutation | rs191455803 | c.962N>A | p.Arg321Gln | p.R321Q | Q96KC8 | protein_coding | tolerated(0.13) | benign(0.003) | TCGA-BR-8680-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR |
| DNAJC1 | SNV | Missense_Mutation | c.1492N>G | p.Thr498Ala | p.T498A | Q96KC8 | protein_coding | deleterious(0.01) | possibly_damaging(0.847) | TCGA-HU-A4G8-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD | |
| DNAJC1 | SNV | Missense_Mutation | rs536392895 | c.1364N>T | p.Ala455Val | p.A455V | Q96KC8 | protein_coding | tolerated(0.56) | benign(0.041) | TCGA-HU-A4GQ-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| DNAJC1 | deletion | Frame_Shift_Del | c.578delN | p.Lys193ArgfsTer22 | p.K193Rfs*22 | Q96KC8 | protein_coding | TCGA-BR-8487-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
| DNAJC1 | deletion | Frame_Shift_Del | rs767116339 | c.629delN | p.Asn210MetfsTer5 | p.N210Mfs*5 | Q96KC8 | protein_coding | TCGA-BR-8591-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | ||
| DNAJC1 | deletion | Frame_Shift_Del | c.578delN | p.Lys193ArgfsTer22 | p.K193Rfs*22 | Q96KC8 | protein_coding | TCGA-CD-A4MI-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | PD | |||
| DNAJC1 | deletion | Frame_Shift_Del | c.578delN | p.Lys193ArgfsTer22 | p.K193Rfs*22 | Q96KC8 | protein_coding | TCGA-CG-5721-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |||
| DNAJC1 | deletion | Frame_Shift_Del | rs767116339 | c.629delN | p.Asn210MetfsTer5 | p.N210Mfs*5 | Q96KC8 | protein_coding | TCGA-F1-6874-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
| DNAJC1 | SNV | Missense_Mutation | novel | c.1037C>A | p.Pro346Gln | p.P346Q | Q96KC8 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E8-A2EA-01 | Thyroid | thyroid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DNAJC1 | insertion | In_Frame_Ins | novel | c.1504_1505insGCTCTAGGG | p.Gln502delinsArgSerArgGlu | p.Q502delinsRSRE | Q96KC8 | protein_coding | TCGA-ET-A40S-01 | Thyroid | thyroid carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |